Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
18.93
+2.94 (18.39%)
Aug 13, 2025, 4:00 PM - Market closed
Korro Bio Revenue
Korro Bio had revenue of $1.46M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $6.28M. In the year 2024, Korro Bio had annual revenue of $2.27M.
Revenue (ttm)
$6.28M
Revenue Growth
n/a
P/S Ratio
28.22
Revenue / Employee
$60,394
Employees
104
Market Cap
177.77M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.27M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKRRO News
- 2 days ago - Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 24 days ago - Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 - GlobeNewsWire
- 3 months ago - Korro to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Korro Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer - GlobeNewsWire
- 5 months ago - Korro Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 months ago - KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency - GlobeNewsWire
- 6 months ago - Korro to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire